首頁 > 市場調查報告書 > 製藥

血友病市場規模、佔有率和成長分析（按類型、產品、療法、治療方法和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1897172

血友病市場規模、佔有率和成長分析（按類型、產品、療法、治療方法和地區分類）—2026-2033年產業預測

Hemophilia Market Size, Share, and Growth Analysis, By Type, By Product, By Therapy, By Treatment, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，血友病市場規模將達到 143.9 億美元，到 2025 年將達到 153.4 億美元，到 2033 年將達到 255.8 億美元，在預測期（2026-2033 年）內，複合年成長率為 6.6%。

血友病市場正經歷強勁成長，這主要得益於基因療法的近期核准以及眾多處於不同研發階段的候選藥物。民眾對血友病的認知度不斷提高，以及政府為促進新生兒早期篩檢所採取的舉措，進一步推動了市場擴張。血友病是一種性連鎖遺傳疾病，主要影響男性，這導致其盛行率較高。全球調查顯示，血友病患者群體龐大，其中相當一部分患者被診斷為血友病A、B和非特異性血友病。如此高的盛行率直接促使更多人接受治療方法，從而進一步推動了市場發展。隨著相關人員致力於創新療法，血友病領域可望持續發展壯大。

血友病市場促進因素

血友病市場的主要驅動力是基因療法、重組凝血因子濃縮物和個人化醫療等治療方法的顯著進步。這些創新治療方法正在改變血友病的治療方式，顯著改善患者的治療效果，並大幅提升他們的生活品質。隨著新的治療方案不斷湧現，不僅治療效果更加顯著，患者還能獲得更個人化的解決方案，滿足其個別需求，最終推動血友病市場的發展和演變，因為醫療服務提供者正努力提供最佳的醫療服務。

血友病市場限制因素

由於治療費用高昂，尤其是基因療法等創新治療方法的高成本，血友病市場面臨巨大的限制。這些經濟負擔嚴重阻礙了患者尋求有效治療，並常常限制了他們獲得先進治療方案的機會。醫療系統也可能因提供這些先進療法而承受沉重的經濟負擔。血友病市場固有的經濟挑戰有可能影響患者的治療效果，並阻礙治療領域的整體進展，因此亟需更經濟實惠的解決方案，以改善有需要人群的醫療服務。

血友病市場趨勢

血友病領域的一個顯著市場趨勢是基因療法的日益普及。這種治療方法有望透過靶向疾病的潛在遺傳問題，徹底改變治療模式。這種創新方法旨在引入功能性基因，使患者能夠合成必需的凝血因子，從而顯著改善其生活品質。病毒載體技術的進步和對基因操作更深入的理解推動了基因療法的發展。大量臨床試驗已顯示出令人鼓舞的結果，表明基因療法可能提供一種持久的解決方案，並減少對傳統因子替代療法的持續依賴。這正在重塑血友病的治療模式。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Bayer AG（Germany）
BioMarin Pharmaceutical Inc.（United States）
CSL Behring（Australia）
Kedrion（Italy）
Novo Nordisk（Denmark）
Pfizer Inc.（United States）
Roche（Chugai Pharmaceutical Co.）（Switzerland/Japan）
Sanofi（Genzyme Corporation）（France/United States）
Takeda Pharmaceutical（Shire Plc.）（Japan/Ireland）
Grifols（Spain）
Octapharma（Switzerland）
F. Hoffmann-La Roche Ltd（Switzerland）
Biogen（United States）
Baxalta（United States）
LFB Group（France）
Bioverativ Inc.（United States）
Bio Products Laboratory Ltd.（United Kingdom）
Kogenate（Germany）
Sangamo Therapeutics, Inc.（United States）

結論與建議

簡介目錄

Product Code: SQMIG35D2191

Hemophilia Market size was valued at USD 14.39 Billion in 2024 and is poised to grow from USD 15.34 Billion in 2025 to USD 25.58 Billion by 2033, growing at a CAGR of 6.6% during the forecast period (2026-2033).

The hemophilia treatment market is experiencing robust growth fueled by the recent approvals of gene therapies and a wealth of candidates in various stages of development. Enhanced awareness of hemophilia, coupled with government initiatives promoting early detection in newborns, further bolsters market expansion. The disorder predominantly affects males due to its sex-linked nature, contributing to its prevalence. Global surveys reveal a significant patient population, with many individuals diagnosed with types A, B, and unspecified hemophilia. This high prevalence is directly influencing the rising adoption of therapies, reinforcing the market's momentum. As stakeholders focus on innovative treatment solutions, the hemophilia landscape is poised for continued evolution and growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemophilia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemophilia Market Segments Analysis

Global Hemophilia Market is segmented by Type, Product, Therapy, Treatment and region. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, Hemophilia C and Others. Based on Product, the market is segmented into Plasma derived coagulation factor concentrates, Recombinant coagulation factor concentrates and Desmopressin and antifibrinolytic agents. Based on Therapy, the market is segmented into On-demand and Prophylaxis. Based on Treatment, the market is segmented into Replacement therapy, ITI therapy and Gene Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemophilia Market

The hemophilia market is primarily driven by significant advancements in treatment approaches, including gene therapy, recombinant factor concentrates, and personalized medicine. These innovative therapies have transformed the management of hemophilia, leading to better patient outcomes and a marked improvement in overall quality of life for those affected by the disorder. As new treatment options continue to emerge, they not only enhance the efficacy of care but also offer patients more tailored solutions that meet their individual needs, ultimately contributing to the growth and evolution of the hemophilia market as healthcare providers seek to deliver optimal care.

Restraints in the Hemophilia Market

The hemophilia market faces significant constraints due to the high costs associated with treatments, especially innovative therapies like gene therapy. These financial burdens can create substantial obstacles for patients seeking effective care, often limiting their access to advanced therapeutic options. Healthcare systems may also experience strain as they navigate the expenses related to providing these sophisticated treatments. The economic challenges inherent in the hemophilia market can impede patient outcomes and hinder the overall progress of therapeutic advancements, emphasizing the need for more affordable solutions to enhance accessibility for individuals requiring care.

Market Trends of the Hemophilia Market

A prominent market trend in the hemophilia sector is the increasing integration of gene therapy, which is poised to transform treatment paradigms by targeting the root genetic issues of the disorder. This innovative approach aims to deliver functional genes that enable patients to synthesize essential clotting factors, significantly enhancing their quality of life. The rise of gene therapy is fueled by advancements in viral vector methodologies and a deeper comprehension of genetic manipulation. Numerous clinical trials have reported encouraging outcomes, indicating that gene therapy could offer enduring solutions and alleviate the ongoing need for conventional factor replacement therapies, thereby reshaping the treatment landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Hemophilia Market Size by Type & CAGR (2026-2033)

Market Overview
Hemophilia A
Hemophilia B
Hemophilia C
Others

Global Hemophilia Market Size by Product & CAGR (2026-2033)

Market Overview
Plasma derived coagulation factor concentrates
Recombinant coagulation factor concentrates
Desmopressin and antifibrinolytic agents

Global Hemophilia Market Size by Therapy & CAGR (2026-2033)

Market Overview
On-demand
Prophylaxis

Global Hemophilia Market Size by Treatment & CAGR (2026-2033)

Market Overview
Replacement therapy
ITI therapy
Gene Therapy

Global Hemophilia Market Size & CAGR (2026-2033)

North America (Type, Product, Therapy, Treatment)
- US
- Canada
Europe (Type, Product, Therapy, Treatment)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Product, Therapy, Treatment)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Product, Therapy, Treatment)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Product, Therapy, Treatment)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (Genzyme Corporation) (France/United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical (Shire Plc.) (Japan/Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxalta (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioverativ Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Products Laboratory Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kogenate (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments